PMID- 35912266
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220802
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Recent Advances on the Role of ATGL in Cancer.
PG  - 944025
LID - 10.3389/fonc.2022.944025 [doi]
LID - 944025
AB  - The hypoxic state of the tumor microenvironment leads to reprogramming lipid 
      metabolism in tumor cells. Adipose triglyceride lipase, also known 
      as patatin-like phospholipase= domain-containing protein 2 and Adipose 
      triglyceride lipase (ATGL), as an essential lipid metabolism-regulating enzyme in 
      cells, is regulated accordingly under hypoxia induction. However, studies 
      revealed that ATGL exhibits both tumor-promoting and tumor-suppressing effects, 
      which depend on the cancer cell type and the site of tumorigenesis. For example, 
      elevated ATGL expression in breast cancer is accompanied by enhanced fatty acid 
      oxidation (FAO), enhancing cancer cells' metastatic ability. In prostate cancer, 
      on the other hand, tumor activity tends to be negatively correlated with ATGL 
      expression. This review outlined the regulation of ATGL-mediated lipid metabolism 
      pathways in tumor cells, emphasizing the Hypoxia-inducible factors 
      1 (HIF-1)/Hypoxia-inducible lipid droplet-associated (HIG-2)/ATGL axis, 
      peroxisome proliferator-activated receptor (PPAR)/G0/G1 switch gene 2 (G0S2)/ATGL 
      axis, and fat-specific protein 27 (FSP-27)/Early growth response protein 1 
      (EGR-1)/ATGL axis. In the light of recent research on different cancer types, the 
      role of ATGL on tumorigenesis, tumor proliferation, and tumor metastasis was 
      systemically reviewed.
CI  - Copyright (c) 2022 Zhang, Meng, Yang, Liu, Shi, Zeng, Chang, Liang, Liu and Xing.
FAU - Zhang, Renshuai
AU  - Zhang R
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao, China.
AD  - Qingdao Cancer Institute, Qingdao, China.
FAU - Meng, Jingsen
AU  - Meng J
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao, China.
AD  - Qingdao Cancer Institute, Qingdao, China.
FAU - Yang, Shanbo
AU  - Yang S
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao, China.
AD  - Qingdao Cancer Institute, Qingdao, China.
FAU - Liu, Wenjing
AU  - Liu W
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao, China.
AD  - Qingdao Cancer Institute, Qingdao, China.
FAU - Shi, Lingyu
AU  - Shi L
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao, China.
AD  - Qingdao Cancer Institute, Qingdao, China.
FAU - Zeng, Jun
AU  - Zeng J
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao, China.
AD  - Qingdao Cancer Institute, Qingdao, China.
FAU - Chang, Jing
AU  - Chang J
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao, China.
AD  - Qingdao Cancer Institute, Qingdao, China.
FAU - Liang, Bing
AU  - Liang B
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao, China.
AD  - Qingdao Cancer Institute, Qingdao, China.
FAU - Liu, Ning
AU  - Liu N
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao, China.
AD  - Qingdao Cancer Institute, Qingdao, China.
FAU - Xing, Dongming
AU  - Xing D
AD  - Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao, China.
AD  - Qingdao Cancer Institute, Qingdao, China.
AD  - School of Life Sciences, Tsinghua University, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220713
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9326118
OTO - NOTNLM
OT  - Adipose triglyceride lipase (ATGL)
OT  - HIF-1
OT  - cancer
OT  - hypoxia
OT  - lipid metabolism
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/08/02 06:00
MHDA- 2022/08/02 06:01
PMCR- 2022/01/01
CRDT- 2022/08/01 03:59
PHST- 2022/05/14 00:00 [received]
PHST- 2022/06/15 00:00 [accepted]
PHST- 2022/08/01 03:59 [entrez]
PHST- 2022/08/02 06:00 [pubmed]
PHST- 2022/08/02 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.944025 [doi]
PST - epublish
SO  - Front Oncol. 2022 Jul 13;12:944025. doi: 10.3389/fonc.2022.944025. eCollection 
      2022.